RCT in 52 kidney transplant recipients: dapagliflozin vs placebo for 12 weeks did not lower systolic BP (primary); it reduced mean arterial pressure at 1 week (3.9 mm Hg) and measured GFR, increased glucosuria and was well tolerated.
RCTn = 52
Sridhar et al. Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial